Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Two gene prognostic biomarker studies demonstrate clinical utility of H:I Index
January 5th, 2006
Arcturus Bioscience presented results from two internal clinical studies validating the company's proprietary two gene index, HOXB13:IL-17BR (H:I Index), as a potential prognostic biomarker for the assessment of disease recurrence risk in breast cancer patients at the 28th Annual San Antonio Breast Cancer Symposium. Arcturus and Massachusetts General Hospital previously described the discovery of the H:I Index as a predictor of clinical outcome in breast cancer patients receiving hormonal therapy. At the Breast Cancer Symposium, Arcturus presented two independent studies with Mayo Clinic and the Baylor Breast Cancer Center that confirm this original finding. ...
Source: Women's Health Weekly (2006-01-05)
|
